EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

The Human Urate Transportosome: Evolutionary Dynamics, Molecular Mechanisms, and Pharmacogenetic Perspectives

Lilya U Dzhemileva iD, Vladimir A D'yakonov iD, Sergey N Marshala iD, Elza Khusnutdinova iD, Andrey A Deviatkin iD, German A Shipulin iD

Medical Sciences · 2026

DOI: 10.3390/medsci14060612 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Medical Sciences, 2026. Verfasst von Lilya U Dzhemileva und 5 weiteren Autor:innen. Beteiligte Einrichtung: N.D. Zelinsky Institute of Organic Chemistry, Russian Academy of Sciences, Leninsky Prospect 47, Moscow 119991, Russia. Hauptthemen laut MEDLINE: Uric Acid, Pharmacogenetics. Die Arbeit nennt 193 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The hominoid loss of urate oxidase (uricase) represents a classic evolutionary trade-off, shifting uric acid (UA) from a metabolic waste product to a potent physiological modulator. In modern metabolic environments, however, this adaptation drives hyperuricemia and gout, transforming UA into a primary pathological substrate.

Objective

This review aims to dissect the molecular architecture and biophysical networks of the renal and intestinal urate transportosome, delineate the dual intracellular/extracellular “urate paradox,” and synthesize genotype-based pharmacogenetic strategies to achieve personalized clinical management. Mechanistic Insights: During the Miocene epoch, inactivating pseudogenization of the UOX gene fixed a novel metabolic phenotype characterized by fructose-driven lipid deposition and enhanced antioxidant protection. Structurally, systemic urate homeostasis is strictly governed by a macromolecular interactome assembled by the four-domain scaffold protein PDZK1 on the epithelial apical membrane. Pathogenic gain-of-function variants in reabsorption facilitators (SLC22A12/URAT1, SLC2A9/GLUT9) or loss-of-function mutations in the efflux pump (ABCG2/BCRP) disrupt this delicate vector kinetics. Within the extracellular space, soluble urate acts as a critical hydrophilic radical scavenger. Paradoxically, upon URAT1/GLUT9-mediated internalization or intracellular supersaturation, intracellular urate triggers a pro-oxidant cascade mediated by NADPH oxidase (NOX4) activation and mitochondrial electron transport chain decoupling. This chronic cellular stress activates downstream p38 MAPK and NF-κB signaling pathways, driving localized endothelial injury and macrovascular inflammation, while crystalline monosodium urate (MSU) orchestrates NLRP3 inflammasome assembly in macrophages. Pharmacogenetic Implications: Striking ethno-geographic heterogeneity dictates immediate clinical stratification. The HLA-B*58:01 allele, an absolute molecular contraindication for allopurinol due to life-threatening severe cutaneous adverse reactions (SCARs), exhibits a critical genetic gradient in northern and eastern Eurasian populations, surging from under 1% in ethnic Caucasians to over 10% in indigenous populations of East/North Asian ancestry. Furthermore, structural defects in ABCG2 (such as the p.Q141K variant) alter the ATP-binding cassette domain, inducing standard allopurinol resistance and elevated statin exposure, which mandates a therapeutic pivot toward selective xanthine oxidase inhibitors (febuxostat) or precision uricosurics (benzbromarone, dotinurad) matched to the patient’s interactive network profile.

Conclusions

Transitioning from generalized epidemiological guidelines to a comprehensive “transportosome genetic passport” is a fundamental prerequisite for predicting single-nucleotide polymorphism (SNP)-driven therapeutic responses and mitigating visceral complications.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Uric AcidPharmacogeneticsHumansHyperuricemiaOrganic Anion TransportersOrganic Cation Transport ProteinsUrate OxidaseGoutGlucose Transport Proteins, FacilitativeATP Binding Cassette Transporter, Subfamily G, Member 2AnimalsNeoplasm Proteins

Stichwörter der Autor:innen

ABCG2HLA-B*58:01SLC2A9gouthyperuricemiapharmacogenomicsurate transportosome

Substanzen

Uric AcidOrganic Anion TransportersOrganic Cation Transport ProteinsUrate OxidaseSLC22A12 protein, humanGlucose Transport Proteins, FacilitativeABCG2 protein, humanSLC2A9 protein, humanATP Binding Cassette Transporter, Subfamily G, Member 2Neoplasm Proteins

Autor:innen und Institutionen

  • N.D. Zelinsky Institute of Organic Chemistry, Russian Academy of Sciences, Leninsky Prospect 47, Moscow 119991, Russia.
  • Federal State Budgetary Institution "Centre for Strategic Planning and Management of Biomedical Health Risks" of the Federal Medical and Biological Agency, Pogodinskaya Str. 10/1, Moscow 119121, Russia.
  • JSC "Medsi Group of Companies", Michurinsky Prospekt 56/1, Moscow 119192, Russia.
  • Department of Medical Genetics and Fundamental Medicine, Bashkir State Medical University, Ufa 450008, Russia.
  • Department of Propaedeutics of Internal Diseases No. 2, Institute of Clinical Medicine, Pirogov Russian National Research Medical University, Moscow 117513, Russia.

ORCID-Profile: Lilya U Dzhemileva, Vladimir A D'yakonov, Sergey N Marshala, Elza Khusnutdinova, Andrey A Deviatkin, German A Shipulin

Zitieren

APA

Dzhemileva, L. U., D'yakonov, V. A., Marshala, S. N., Khusnutdinova, E., Deviatkin, A. A., & Shipulin, G. A. (2026). The Human Urate Transportosome: Evolutionary Dynamics, Molecular Mechanisms, and Pharmacogenetic Perspectives. Medical Sciences. https://doi.org/10.3390/medsci14060612

Vancouver

Dzhemileva LU, D'yakonov VA, Marshala SN, Khusnutdinova E, Deviatkin AA, Shipulin GA. The Human Urate Transportosome: Evolutionary Dynamics, Molecular Mechanisms, and Pharmacogenetic Perspectives. Medical Sciences. 2026. doi:10.3390/medsci14060612

BibTeX
@article{Dzhemileva2026,
  author = {Dzhemileva, Lilya U and D'yakonov, Vladimir A and Marshala, Sergey N and Khusnutdinova, Elza and Deviatkin, Andrey A and Shipulin, German A},
  title = {The Human Urate Transportosome: Evolutionary Dynamics, Molecular Mechanisms, and Pharmacogenetic Perspectives},
  journal = {Medical Sciences},
  year = {2026},
  doi = {10.3390/medsci14060612}
}
Kostenlos starten →